Novo Nordisk will slash U.S. record costs of its blockbuster diabetes and weight-loss medicine Ozempic and Wegovy by as much as 50% beginning subsequent yr, the Danish drugmaker stated on Tuesday.
The worth cuts shall be efficient January 1 subsequent yr, coinciding with the implementation of latest, decrease costs for a similar medicine beneath federal Medicare well being plans for older adults.
The marketplace for so-called GLP-1 medicine has been getting more and more aggressive, whereas the broader shift to consumer-driven cash-pay channels is making worth factors extra delicate.
Each Ozempic and Wegovy will record for $675 a month from subsequent yr, half the present worth for Wegovy and a 35% lower for diabetes remedy Ozempic.
The worth cuts additionally will apply to Wegovy and Rybelsus drugs.
This determination applies to all doses of those medicines and displays Novo Nordisk’s dedication to enhancing affordability for sufferers and each private and non-private payers coping with the complexities of the evolving U.S. healthcare system, the corporate stated.
